VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

I doubt it as the NIMH Phase Monotherapy should be out in the summer. That could be a bigger catalyst than the patent.

I would suggest you read Chardon research report calling for $22.00 VTGN.

This space is becoming very interesting as new classes of drugs are getting traction to help people suffering from depression, which is at epidemic levels.

In fact, some people are resorting to very high priced ketamine clinics for help. There is no insurance coverage for clinics like this and the treatments are very expensive.

https://www.google.com/search?q=ketamine+clinics+in+usa&rlz=1C1CHZL_enUS738US738&oq=ketamine+clinics+in+US&aqs=chrome.0.0j69i57j0.7011j0j7&sourceid=chrome&ie=UTF-8


For example, visit http://portlandketamineclinic.com/PKC/

The failure of the current class of depression drugs (that are mostly generic now) and the horrible side effects are why big pharma is now embracing these new and hopefully safe class of treatments.